These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16316710)

  • 21. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
    Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
    Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.
    Chung Y; Kim BS; Kim YJ; Ko HJ; Ko SY; Kim DH; Kang CY
    Cancer Res; 2006 Jul; 66(13):6843-50. PubMed ID: 16818662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
    Najar HM; Dutz JP
    Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
    Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
    Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model.
    Cui Z; Qiu F
    Cancer Immunol Immunother; 2006 Oct; 55(10):1267-79. PubMed ID: 16362407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
    Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
    Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
    Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
    Schlosser E; Mueller M; Fischer S; Basta S; Busch DH; Gander B; Groettrup M
    Vaccine; 2008 Mar; 26(13):1626-37. PubMed ID: 18295941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
    Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
    Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.
    Mizukami S; Kajiwara C; Ishikawa H; Katayama I; Yui K; Udono H
    Cancer Sci; 2008 May; 99(5):1008-15. PubMed ID: 18341654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
    Kammer AR; Amacker M; Rasi S; Westerfeld N; Gremion C; Neuhaus D; Zurbriggen R
    Vaccine; 2007 Oct; 25(41):7065-74. PubMed ID: 17766014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunobiology of the Tomatine adjuvant.
    Morrow WJ; Yang YW; Sheikh NA
    Vaccine; 2004 Jun; 22(19):2380-4. PubMed ID: 15193398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
    Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
    Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.